Monopar Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Monopar Therapeutics Inc. (MNPR) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $56.63 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $16.98, a 357.68% increase year-over-year.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $3.71.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.00.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $21.99, a 38.48% increase from fiscal 2024.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $15.88, a 19.27% decline from fiscal 2023.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $19.67, a 220.88% increase from fiscal 2022.
- Monopar Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $6.13.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $56.63 10-Q · filed 2026-08-12 | ||||
| 2026-03-31 | $16.98 10-Q · filed 2026-05-14 | ||||
| 2025-12-31 | $21.99 10-K · filed 2026-03-27 | ||||
| 2025-09-30 | $9.70 10-Q · filed 2025-11-13 | ||||
| 2025-06-30 | $5.58 10-Q · filed 2025-08-12 | ||||
| 2025-03-31 | $3.71 10-Q · filed 2025-05-13 | ||||
| 2024-12-31 | $15.88 10-K · filed 2026-03-27 | ||||
| 2024-09-30 | $15.88 10-Q · filed 2024-11-08 | ||||
| 2024-06-30 | $0.00 10-Q · filed 2024-08-09 | ||||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | $19.67 10-K · filed 2025-03-31 | $3.93 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $3.93 10-Q · filed 2023-11-09 | ||||
| 2023-06-30 | $4.10 10-Q · filed 2023-08-10 | ||||
| 2022-12-31 | $6.13 10-K · filed 2024-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |